HER2DX: Advances in targeted treatment of HER2-positive breast cancer

被引：0
|
作者：
Andujar, Juan M. Cejalvo [1 ]
机构：
[1] Hosp Clin Univ Valencia, Dept Oncol Med, Inst Invest Sanitaria INCL, Valencia, Spain
来源：
REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA | 2024年 / 37卷 / 03期
关键词：
D O I：
10.1016/j.senol.2024.100615
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] HER2DX: a tool that might inform treatment choices for HER2-positive breast cancer
    Hurvitz, Sara A.
    LANCET ONCOLOGY, 2020, 21 (11): : 1392 - 1393
  • [2] Investigating HER2DX genomic assay concordance within HER2-positive breast cancer
    Braso-Maristany, Fara
    Pare, Laia
    Villacampa, Guillermo
    Marin-Aguilera, Mercedes
    Spellman, Paul
    Waks, Adrienne
    Krop, Ian
    Sanfeliu, Esther
    Li, Zhequi
    Galvan, Patricia
    Hernandez-Illan, Eva
    Jares, Pedro
    Puig-Butille, Joan Anton
    Vivancos, Ana
    Villagrasa, Patricia
    Parker, Joel S.
    Perou, Charles M.
    Tolaney, Sara
    Metzger, Otto
    Polyak, Kornelia
    Prat, Aleix
    CANCER RESEARCH, 2024, 84 (09)
  • [3] Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
    Villacampa, G.
    Tung, N. M.
    Pernas, S.
    Pare, L.
    Bueno-Muino, C.
    Echavarria, I.
    Lopez-Tarruella, S.
    Roche-Molina, M.
    del Monte-Millan, M.
    Marin-Aguilera, M.
    Braso-Maristany, F.
    Waks, A. G.
    Pascual, T.
    Martinez-Saez, O.
    Vivancos, A.
    Conte, P. F.
    Guarneri, V.
    Dieci, M. Vittoria
    Griguolo, G.
    Cortes, J.
    Llombart-Cussac, A.
    Munoz, M.
    Vidal, M.
    Adamo, B.
    Wolff, A. C.
    Demichele, A.
    Villagrasa, P.
    Parker, J. S.
    Perou, C. M.
    Fernandez-Martinez, A.
    Carey, L. A.
    Mittendorf, E. A.
    Martin, M.
    Prat, A.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2023, 34 (09) : 783 - 795
  • [4] Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer
    Dieci, Maria Vittoria
    Conte, Pierfranco
    Bisagni, Giancarlo
    Bartolini, Stefania
    Frassoldati, Antonio
    Generali, Daniele
    Piacentini, Federico
    Griguolo, Gaia
    Tagliafico, Enrico
    Braso Maristany, Fara
    Chic, Nuria
    Pare, Laia
    Miglietta, Federica
    Vicini, Roberto
    D'Amico, Roberto
    Balduzzi, Sara
    Prat, Aleix
    Guarneri, Valentina
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (01): : 69 - 80
  • [5] Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer
    Marin-Aguilera, M.
    Jares, P.
    Sanfeliu, E.
    Villacampa, G.
    Hernandez-lllan, E.
    Martinez-Puchol, A. I.
    Shankar, S.
    Gonzalez-Farre, B.
    Waks, A. G.
    Braso-Maristany, F.
    Pardo, F.
    Manning, D. K.
    Abery, J. A.
    Curaba, J.
    Moon, L.
    Gordon, O.
    Galvan, P.
    Wachirakantapong, P.
    Castillo, O.
    Nee, C. M.
    Blasco, P.
    Senevirathne, T. H.
    Sirenko, V.
    Martinez-Saez, O.
    Aguirre, A.
    Krop, I. E.
    Li, Z.
    Spellman, P.
    Metzger Filho, O.
    Polyak, K.
    Michaels, P.
    Puig-Butille, J. A.
    Vivancos, A.
    Matito, J.
    Buckingham, W.
    Perou, C. M.
    Villagrasa-Gonzalez, P.
    Prat, A.
    Parker, J. S.
    Pare, L.
    ESMO OPEN, 2024, 9 (03)
  • [6] Personalized treatment approaches with HER2DX in early HER2-positive breast cancer: A precision tool for treatment decision-making
    Cespedes, M. Tapia
    Cussac, A. Llombart
    Tebar, C.
    Liebana, S. M.
    Molina, A. Magro
    Abad, L. Palomar
    Martinez, M. T. M.
    Melia, C. Hernando
    Iranzo, V.
    Pouptsis, A.
    Bertran, A. Santaballa
    Maicas, M. D. Torregrosa
    Burgues, O.
    Cano, I. Garrido
    Lluch-Hernandez, A.
    Gonzalez, P. Villagrasa
    Prat, A.
    bermejo, B.
    Cejalvo, J. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S332 - S332
  • [7] HER2DX genomic assay in advanced HER2-positive (HER2+) breast cancer treated with T-DM1
    Braso-Maristany, F.
    Griguolo, G.
    Chic, N.
    Pare Brunet, L.
    Galvan, P.
    Dieci, M. V.
    Miglietta, F.
    Giarratano, T.
    Martinez-Saez, O.
    Marin, M.
    Vidal Losada, M. J.
    Adamo, B.
    Munoz, M.
    Vivancos, A.
    Villagrasa Gonzalez, P.
    Parker, J.
    Perou, C. M.
    Conte, P. F.
    Prat, A.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S646 - S646
  • [8] HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers5
    Lynce, F.
    Martinez-Saez, O.
    Walbaum, B.
    Braso-Maristany, F.
    Waks, A. G.
    Villagrasa, P.
    Javierre, G. Villacampa
    Sanfeliu, E.
    Galvan, P.
    Pare, L.
    Anderson, L. M.
    Perou, C. M.
    Parker, J. S.
    Vivancos, A.
    Dilullo, M. K.
    Pernas, S.
    Winer, E. P.
    Overmoyer, B.
    Mittendorf, E. A.
    Bueno-Muino, C.
    Martin, M.
    Prat, A.
    Tolaney, S. M.
    ESMO OPEN, 2025, 10 (02)
  • [9] Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer
    Ismaili, Nabil
    Belbaraka, Rhizlane
    Elomrani, Abdelhamid
    Khouchani, Mouna
    Tahri, Ali
    PRESSE MEDICALE, 2013, 42 (11): : 1461 - 1468
  • [10] Can we use HER2DX to modulate treatment intensity in HER2 positive early breast cancer?
    De Castro, Beatriz Alonso
    Rendo, Cristina Reboredo
    Mosele, Fernanda
    Lopez, Eva Perez
    Martinez, Lourdes Calvo
    Novoa, Silvia Antolin
    REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2025, 38 (03):
12345